Frontier Medicines to Highlight Lead Candidate, Novel Twin KRASG12C Inhibitor FMC-376, and the Frontier™ Platform on the 2023 AACR Annual Assembly

Frontier Medicines

Frontier Medicines

BOSTON and SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) — Frontier Medicines Company, a precision drugs firm searching for to unlock the proteome to advance breakthrough therapies towards in any other case undruggable disease-causing targets, at the moment introduced upcoming displays that includes preclinical knowledge on its novel twin KRASG12C inhibitor FMC-376 and advances from the Frontier™ Platform. These knowledge can be introduced on the upcoming American Affiliation for Most cancers Analysis (AACR) Annual Assembly going down April 14th-19th in Orlando, Florida.

Preclinical knowledge unveiling FMC-376’s discovery and distinctive mode of motion can be featured in an oral mini-symposium on Small Molecule Therapeutic Brokers on April 16th, adopted by a presentation on the Frontier Platform in an April 18th poster session.

“A long time after the human genome mission, there stays a excessive unmet want for efficient and sturdy breakthrough precision medicines focusing on beforehand undruggable targets like KRAS,” stated Chris Varma, Ph.D., Frontier’s co-founder, chairman, and CEO. “We’re excited to share knowledge exhibiting how our novel twin inhibitor FMC-376 is designed to quickly and straight shut down each lively and inactive KRASG12C. These findings additional validate the power of the Frontier™ Platform to unlock the proteome for the invention of remedies that may probably create a greater future for individuals with most cancers and different severe circumstances.”

Particulars on the displays are as follows:

Presentation Info


Discovery of FMC-376 a novel orally bioavailable inhibitor of activated KRASG12C

Summary Quantity:


Oral Session Title:

Small Molecule Therapeutic Brokers

Session Date and Time:

Sunday, April 16, 2023, 3-5 p.m. ET




Combining chemoproteomics with machine studying identifies functionally lively covalent fragments for hard-to-drug most cancers drivers

Summary Quantity:


Poster Session Title:

Excessive-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery

Session Date and Time:

Tuesday, April 18, 2023, 1:30-5 p.m. ET



About Frontier Medicines
Frontier Medicines is a precision drugs firm that has pioneered a robust drug discovery engine, the Frontier™ Platform, designed to generate medicines towards disease-causing proteins beforehand thought of undruggable. The corporate is deploying its applied sciences in chemoproteomics, covalent drug discovery, and machine studying to develop probably groundbreaking medicines for genetically-defined affected person populations, beginning in most cancers. Frontier is advancing a deep pipeline of wholly-owned precision medicines towards a very powerful drivers of most cancers. The corporate’s lead candidate, FMC-376, is a twin inhibitor of lively and inactive KRASG12C. By fully blocking each types of the KRAS mutation, FMC-376 has the potential to beat the non-response and resistance seen with single-acting KRASG12C inhibitors. For extra info on how Frontier is boldly advancing science to defeat illness, go to and observe us on LinkedIn and Twitter.

Investor and Media Relations Contact:
Victoria Fort
VP, Company Affairs
[email protected]

Supply hyperlink